Annals of Surgical Oncology

, Volume 25, Supplement 3, pp 834–835 | Cite as

ASO Author Reflections: Should We Be Using Dextrose-Containing Carrier Solutions for Perfusion During HIPEC?

  • Camille L. StewartEmail author
  • Martin McCarter
ASO Author Reflections



The authors have no conflicts of interest to disclose.


  1. 1.
    Verwaal VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003; 21:3737–43.CrossRefGoogle Scholar
  2. 2.
    Kusamura S, Dominique E, Baratti D, Younan R, Deraco M. Drugs, carrier solutions and temperature in hyperthermic intraperitoneal chemotherapy. J Surg Oncol. 2008; 98:247–252.CrossRefGoogle Scholar
  3. 3.
    Kwon S, Thompson R, Dellinger P, Yanez D Farrohki E, Flum D. Importance of peri-operative glycemic control in general surgery: a report from the surgical care and outcomes assessment program. Ann Surg. 2013: 257:8–14.CrossRefGoogle Scholar
  4. 4.
    Turaga K, Levine E, Barone R et al. Consensus guidelines from the American Society of Peritoneal Surface Malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States. Ann Surg Oncol. 2014; 21:1501–1505.CrossRefGoogle Scholar
  5. 5.
    Stewart CL, Gleisner A, Halpern A, et al. Implications of hyperthermic intraperitoneal chemotherapy perfusion-related hyperglycemia. Ann Surg Oncol. 2018; 25:655–659.CrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2018

Authors and Affiliations

  1. 1.Department of SurgeryThe University of Colorado School of MedicineAuroraUSA

Personalised recommendations